Cholinergic regulation of inflammation

Psychoneuroimmunology, Two-Volume Set

Volumn 1, Issue , 2007, Pages 85-96

  Czura, Christopher J ^a   Rosas Ballina, Mauricio ^a   Tracey, Kevin J ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250378696     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088576-3/50007-1     Document Type: Chapter

References (86)

1. Knudsen P.J., Dinarello C.A., Strom T.B. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J. Immunol. 1986, 137(10):3189-3194.
2. Wang H., Zhang M., Bianchi M., Sherry B., Sama A., Tracey K.J. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc. Natl. Acad. Sci. USA 1998, 95(24):14429-14434.
3. Zhang M., Caragine T., Wang H., et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells, a counterregulatory mechanism that restrains the immune response. J. Exp. Med. 1997, 185(10):1759-1768.
4. Zhang M., Borovikova L.V., Wang H., Metz C., Tracey K.J. Spermine inhibition of monocyte activation and inflammation. Mol. Med. 1999, 5(9):595-605.
5. Zhang M., Wang H., Tracey K.J. Regulation of macrophage activation and inflammation by spermine, a new chapter in an old story. Crit. Care Med. 2000, 28:N60-N66. 4 SUPPL.
6. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med. 1991, 174(6):1549-1555.
7. Hauser C.J., Lagoo S., Lagoo A., et al. Tumor necrosis factor alpha gene expression in human peritoneal macrophages is suppressed by extra-abdominal trauma. Arch. Surg. 1995, 130(11):1186-1191.
8. Oswald I.P., Wynn T.A., Sher A., James S.L. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory fact interferon gammainduced activation. Proc. Natl. Acad. Sci. USA 1992, 89(18):8676-8680.
9. Miller-Graziano C.L., Szabo G., Griffey K., Mehta B., Kodys K., Catalano D. Role of elevated monocyte transforming growth factor beta (TGF beta) production in posttrauma immunosuppression. J Clin. Immunol. 1991, 11(2):95-102.
10. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988, 334(6179):260-262.
11. Bernik T.R., Friedman S.G., Ochani M., et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 2002, 195(6):781-788.
12. Guarini S., Altavilla D., Cainazzo M.M., et al. Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 2003, 107(8):1189-1194.
13. Wang H., Liao H., Ochani M., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 2004, 10(11):1216-1221.
14. Borovikova L.V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405(6785):458-462.
15. Wang H., Yu M., Ochani M., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421(6921):384-388.
16. Saeed R.W., Varma S., Peng-Nemeroff T., et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J. Exp. Med. 2005, 201(7):1113-1123.
17. Dantzer R. Cytokine-induced sickness behavior, mechanisms and implications. Ann. N. Y. Acad. Sci. 2001, 933:222-234.
18. Maier S.F., Goehler L.E., Fleshner M., Watkins L.R. The role of the vagus nerve in cytokine-to-brain communication. Ann. N. Y. Acad. Sci 1998, 840:289-300.
19. Jones J.F., Wang Y., Jordan D. Heart rate responses to selective stimulation of cardiac vagal C fibres in anaesthetized cats, rats and rabbits. J. Physiol. 1995, 489:203-214. Pt 1.
20. Nosaka S., Yasunaga K., Kawano M. Vagus cardioinhibitory fibers in rats. Pflugers Arch 1979, 379(3):281-285.
21. Schwaber J.S., Cohen D.H. Electrophysiological and electron microscopic analysis of the vagus nerve of the pigeon, with PARTicular reference to the cardiac innervation. Brain Res. 1978, 147(1):65-78.
22. Blalock J.E. The immune system as a sensory organ. J. Immunol. 1984, 132(3):1067-1070.
23. Blalock J.E. The immune system as the sixth sense. J. Intern. Med. 2005, 257(2):126-138.
24. Gross P.M., Weindl A. Peering through the windows of the brain. J. Cereb. Blood Flow Metab. 1987, 7(6):663-672.
25. Johnson A.K., Gross P.M. Sensory circumventricular organs and brain homeostatic pathways. FASEB J. 1993, 7(8):678-686.
26. Plotkin S.R., Banks W.A., Kastin A.J. Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J. Neuroimmunol. 1996, 67(1):41-47.
27. Moinuddin A., Morley J.E., Banks W.A. Regional variations in the transport of interleukin-1alpha across the blood-brain barrier in ICR and aging SAMP8 mice. Neuroimmunomodulation 2000, 8(4):165-170.
28. Cunningham E.T.Jr., Wada E., Carter D.B., Tracey D.E., Battey J.F., De Souza E.B. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J. Neurosci. 1992, 12(3):1101-1114.
29. Yabuuchi K., Minami M., Katsumata S., Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Brain. Res. Mol. Brain Res. 1994, 27(1):27-36.
30. Lacroix S., Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat b. J. Neurochem. 1998, 70(2):452-466.
31. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173(6):3916-3924.
32. Ericsson A., Arias C., Sawchenko P.E. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J. Neurosci. 1997, 17(18):7166-7179.
33. Matsumura K., Watanabe Y., Onoe H., Watanabe Y., Hayaishi O. High density of prostaglandin E2 binding sites in the anterior wall of the 3rd ventricle, a possible site of its hyperthermic action. Brain Res 1990, 533(1):147-151.
34. Parrott R.F., Vellucci S.V. Effects of centrally administered prostaglandin EP receptor agonists on febrile and adrenocortical responses in the prepubertal pig. Brain Res. Bull. 1996, 41(2):97-103.
35. Hansen M.K., Nguyen K.T., Goehler L.E., et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton. Neurosci. 2000, 85(1-3):119-126.
36. Hansen M.K., Nguyen K.T., Fleshner M., et al. Effects of vagotomy on serum endotoxin, cytokines, and corticosterone after intraperitoneal lipopolysaccharide. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278(2):R331-R336.
37. Milligan E.D., McGorry M.M., Fleshner M., et al. Subdiaphragmatic vagotomy does not prevent fever following intracerebroventricular prostaglandin E2: further evidence for the importance of vagal afferents in immune-to-brain communication. Brain Res. 1997, 766(1-2):240-243.
38. Ek M., Kurosawa, Lundeberg T., Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J. Neurosci. 1998, 18(22):9471-9479.
39. Goehler L.E., Relton J.K., Dripps D., et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res. Bull. 1997, 43(3):357-364.
40. Adachi A. Thermosensitive and osmoreceptive afferent fibers in the hepatic branch of the vagus nerve. J. Auton. Nerv. Syst 1984, 10(3-4):269-273.
41. Rogers R.C., McTigue D.M., Hermann G.E. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci. Biobehav. Rev. 1996, 20(1):57-66.
42. Smith B.N., Dou P., Barber W.D., Dudek F.E. Vagally evoked synaptic currents in the immature rat nucleus tractus solitarii in an intact in vitro preparation. J. Physiol. 1998, 512(Pt 1):149-162.
43. Pavlov V.A., Wang H., Czura C.J., Friedman S.G., Tracey K.J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 2003, 9(5-8):125-134.
44. Bernik T.R., Friedman S.G., Ochani M., et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J. Vasc. Surg 2002, 36(6):1231-1236.
45. van Westerloo D.J., Giebelen I.A., Florquin S., et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J. Infect. Dis. 2005, 191(12):2138-2148.
46. Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003, 74(6):675-696.
47. Sato E., Koyama S., Okubo Y., Kubo K., Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am. J. Physiol. 1998, 274(6):L970-L979. Pt 1.
48. Kawashima K., Fujii T., Watanabe Y., Misawa H. Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci. 1998, 62(17-18):1701-1705.
49. Proskocil B.J., Sekhon H.S., Jia Y., et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology 2004, 145(5):2498-2506.
50. Ley K. Integration of inflammatory signals by rolling neutrophils. Immunol. Rev. 2002, 186:8-18.
51. Peters K., Unger R.E., Brunner J., Kirkpatrick C.J. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc. Res. 2003, 60(1):49-57.
52. Reinheimer T., Mohlig T., Zimmermann S., Hohle K.D., Wessler I. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea. Am. J. Respir. Crit. Care Med. 2000, 162(2):534-538. Pt 1.
53. Mariggio M.A., Guida L., Laforgia A., et al. Nicotine effects on polymorphonuclear cell apoptosis and lipopolysaccharide-induced monocyte functions. A possible role in periodontal disease?. J. Periodontal Res. 2001, 36(1):32-39.
54. Singh S.P., Kalra R., Puttfarcken P., Kozak A., Tesfaigzi J., Sopori M.L. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol. Appl. Pharmacol. 2000, 164(1):65-72.
55. Sorensen L.T., Nielsen H.B., Kharazmi A., Gottrup F. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery 2004, 136(5):1047-1053.
56. Speer P., Zhang Y., Gu Y., Lucas M.J., Wang Y. Effects of nicotine on intercellular adhesion molecule expression in endothelial cells and integrin expression in neutrophils in vitro. Am. J. Obstet. Gynecol. 2002, 186(3):551-556.
57. Zhang S., Petro T.M. The effect of nicotine on murine CD4 T cell responses. Int. J. Immunopharmacol. 1996, 18(8-9):467-478.
58. Andersson J. The inflammatory reflex-introduction. J. Intern. Med. 2005, 257(2):122-125.
59. de Jonge W.J., van der Zanden E.P. The FO Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 2005, 6(8):844-851.
60. Mills C.M., Hill S.A., Marks R. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol. 1997, 133(7):823-825.
61. Pullan R.D., Rhodes J., Ganesh S., et al. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 1994, 330(2):811-815.
62. Thomas G.A., Rhodes J., Mani V., et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N. Engl. J. Med. 1995, 332(15):988-992.
63. Sandborn W.J., Tremaine W.J., Offord K.P., et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1997, 126(5):364-371.
64. Delbono O., Gopalakrishnan M., Renganathan M., Monteggia L.M., Messi M.L., Sullivan J.P. Activation of the recombinant human alpha 7 nicotinic acetylcholine receptor significantly raises intracellular free calcium. J. Pharmacol. Exp. Ther. 1997, 280(1):428-438.
65. Leonard S., Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob. Res. 2001, 3(3):203-223.
66. De SR.jmone-Cat M.A., Carnevale D., Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2005, 2(1):4.
67. Bianchi M., Ulrich P., Bloom O., et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1995, 1(3):254-266.
68. Bianchi M., Bloom O., Raabe T., et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 1996, 183(3):927-936.
69. Cohen P.S., Nakshatri H., Dennis J., et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl. Acad. Sci. USA 1996, 93(9):3967-3971.
70. D'Souza M.J., Oettinger C.W., Milton G.V., Tracey K.J. Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J. Interferon Cytokine Res. 1999, 19(10):1125-1133.
71. Atkins M.B., Redman B., Mier J., et al. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. 2001, 7(3):486-492.
72. Hommes D., van den B.B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122(1):7-14.
73. Meistrell M.E., III Botchkina G.I., Wang H., et al. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 1997, 8(5):341-348.
74. Arons M.M., Wheeler A.P., Bernard G.R., et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit. Care Med. 1999, 27(4):699-707.
75. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95(5):1122-1125.
76. Sprung C.L., Peduzzi P.N., Shatney C.H., et al. Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. Crit. Care Med. 1990, 18(8):801-806.
77. Yien H.W., Hseu S.S., Lee L.C., Kuo T.B., Lee T.Y., Chan S.H. Spectral analysis of systemic arterial pressure and heart rate signals as a prognostic tool for the prediction of patient outcome in the intensive care unit. Crit. Care Med. 1997, 25(2):258-266.
78. Hermann C., Blanchard E.B. Biofeedback in the treatment of headache and other childhood pain. Appl. Psychophysiol. Biofeedback 2002, 27(2):143-162.
79. Crider A.B., Glaros A.G. A meta-analysis of EMG biofeedback treatment of temporomandibular disorders. J. Orofac. Pain 1999, 13(1):29-37.
80. Middaugh nS.J., Haythornthwaite J.A., Thompson B., et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Appl. Psychophysiol. Biofeedback 2001, 26(4):251-278.
81. Yucha C.B., Clark L., Smith M., Uris P., LaFleur B., Duval S. The effect of biofeedback in hypertension. Appl. Nurs. Res. 2001, 14(1):29-35.
82. McGrady A., Horner J. Role of mood in outcome of biofeedback assisted relaxation therapy in insulin dependent diabetes mellitus. Appl. Psychophysiol. Biofeedback 1999, 24(1):79-88.
83. Gormley E.A. Biofeedback and behavioral therapy for the management of female urinary incontinence. Urol. Clin. North Am. 2002, 29(3):551-557.
84. Pager C.K., Solomon M.J., Rex J., Roberts R.A. Long-term outcomes of pelvic floor exercise and biofeedback treatment for patients with fecal incontinence. Dis. Colon Rectum 2002, 45(8):997-1003.
85. Lehrer P., Smetankin A., Potapova T. Respiratory sinus arrhythmia biofeedback therapy for asthma: a report of 20 unmedicated pediatric cases using the Smetankin method. Appl. Psychophysiol. Biofeedback 2000, 25(3):193-200.
86. Aikens J.E. Thermal biofeedback for claudication in diabetes: a literature review and case study. Altern. Med. Rev. 1999, 4(2):104-110.